Today on the Daily Dive, Jeff Stevens returns to the show to sit down with host Cassandra Leah to discuss that of Psyched Wellness (CSE: PSYC), where he currently serves as CEO. In the latest edition of the Daily Dive, we ask Jeff about that of Compass Pathways, the psychedelics sector as a whole and the competitive edge that Psyched has relative to peers.

Psyched Wellness is a health and wellness firm largely focused on the Amanita Muscaria mushroom, a mushroom with both functional and psychedelic properties to it. The firm as of late has successfully extracted the fungi, for which it is now commencing pre-clinical trials to determine safe dosage levels of the psychedelic compound within the mushroom. Going forward, the company will look to acquire natural health product registration from Health Canada and NDI certification from the FDA to enable the commercialization of supplements based upon the unique fungi.

Catch the full interview below.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

The post Compass Pathways Leader Of Investment Climate For Psychedelic Plays – The Daily Dive feat Jeff Stevens appeared first on the deep dive.